Mr. Speaker, Canada's generic pharmaceutical industry is a true success story, wonderfully reflected in the Apotex facility in my riding of Brant. The industry, however, is justifiably concerned about, and surprised by, recently published regulatory amendments.
These changes are contrary to the best interests of consumers, changes which will delay generic competition and will extend monopolies for brand name companies.
Almost all generic drugs sold in Canada are made here in Canada by 11,000 highly skilled people. The government should withdraw proposals which will harm a dynamic industry and will increase prescription drug costs for Canadians.
The message to the government is to do the right thing and withdraw these amendments.